Compare IDXX & NDAQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDXX | NDAQ |
|---|---|---|
| Founded | 1983 | 1971 |
| Country | United States | United States |
| Employees | 11000 | 9613 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6B | 51.5B |
| IPO Year | 1996 | 2001 |
| Metric | IDXX | NDAQ |
|---|---|---|
| Price | $557.97 | $90.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $721.67 | $105.62 |
| AVG Volume (30 Days) | 578.8K | ★ 2.9M |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | 22.59 | ★ 60.10 |
| EPS | ★ 3.47 | 0.91 |
| Revenue | ★ $4,303,702,000.00 | $4,277,000,000.00 |
| Revenue This Year | $10.88 | $10.52 |
| Revenue Next Year | $8.59 | $8.17 |
| P/E Ratio | $159.66 | ★ $99.22 |
| Revenue Growth | ★ 10.42 | 7.87 |
| 52 Week Low | $504.56 | $77.09 |
| 52 Week High | $769.98 | $101.79 |
| Indicator | IDXX | NDAQ |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 55.09 |
| Support Level | $554.61 | $84.95 |
| Resistance Level | $595.15 | $91.92 |
| Average True Range (ATR) | 19.51 | 1.94 |
| MACD | 1.96 | -0.06 |
| Stochastic Oscillator | 55.62 | 55.31 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its trading business (about 22.5% of sales), the company sells market and financial data to investors, offers Nasdaq-branded indexes, and lists companies through its capital access segment (42.5%). Nasdaq's newest segment, financial technology, was primarily constructed through the acquisitions of Verafin and Adenza and has expanded the company into capital management, financial crime, and regulatory compliance software (35%) as it seeks to become a diversified technology company.